debio-1347
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 10, 2017 (NCT03344536)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 3INHIBITOR
FGFR3 inhibitor
- Fibroblast growth factor receptor 2INHIBITOR
FGFR2 inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- debio-1347
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03834220 | Phase 2 | Mar 1, 2019 | Caris Life Science, Debiopharm, Optimal Research |
| NCT03344536 | Phase 1/Phase 2 (Phase 2) | Nov 10, 2017 | Debiopharm, Memorial Sloan-Kettering Cancer Center |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Debiopharm | For profit | 2 | 1 | 1 | 2017 |
| Caris Life Science | For profit | 1 | 0 | 1 | 2019 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Optimal Research | For profit | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1